证券代码：688198 证券简称：佰仁医疗 公告编号：2025-017 北京佰仁医疗科技股份有限公司2024年年度 权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/5/28 | 2025/5/29 | 2025/5/29 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 15 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 1. 实施办法 除公司自行发放对象外，公司其余股东的红利委托中国结算上海分公司通过 其资金清算系统向股权登记日上海证券交易所收市后登记在册并在上海证券交易 所各会员办理了指定交易的股东派发。已办理指定交易的投资者可于红利发放日 在其指定的证券营业部领取现金红利 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 126.56 CNY [3][2] Core Insights - The company has shown robust revenue growth, with a 2024 revenue forecast of 5.02 billion CNY, representing a year-on-year increase of 35.41%. The net profit attributable to the parent company is projected at 1.46 billion CNY, up 27.02% year-on-year [6][2] - The first quarter of 2025 saw a significant revenue increase to 1.00 billion CNY, a 31.30% year-on-year growth, with net profit soaring by 290.69% to 0.33 billion CNY, attributed to the completion of clinical trials and a decrease in R&D expenses [6][2] - The company is advancing in three major business segments, with new product sales rapidly increasing, particularly in the heart valve replacement and repair segment, which achieved a revenue of 2.29 billion CNY, up 64.28% year-on-year [6][2] Financial Summary - Revenue projections for 2023A to 2027E are as follows: 371 million CNY (2023A), 502 million CNY (2024A), 681 million CNY (2025E), 898 million CNY (2026E), and 1,136 million CNY (2027E) [2][8] - The company’s gross margin is expected to be 88.34% in 2024, with a slight decrease from previous years due to new product costs [6][2] - The net profit margin is projected to be 29.2% in 2024, with a net profit attributable to the parent company of 1.46 billion CNY [2][8] R&D and Product Development - R&D investment reached 1.51 billion CNY in 2024, accounting for 30.17% of revenue, with significant progress in product registrations, including three new products [6][2] - The company is expected to continue expanding its product lineup, with several new products in the pipeline for registration in 2025 [6][2]

Key Insights - The report highlights a focus on several stocks for May, including SF Holding, Jitu Express, and Guizhou Moutai, indicating potential investment opportunities in these companies [1] - The basic chemical industry is expected to see a recovery in profitability as the economy rebounds, with a slight revenue increase of 2.66% year-on-year in 2024, reaching approximately 2,219.98 billion yuan [3][6] - The computer industry experienced a significant improvement in profitability in Q1 2025, with a year-on-year net profit growth of 156.56%, indicating resilience driven by advancements in robotics and AI [11][12] - Lin Yang Energy reported a decline in overall performance for 2024, with a revenue of 6.742 billion yuan, down 1.89% year-on-year, but saw growth in its electric meter business [17][18] Basic Chemicals Industry - The basic chemicals sector's revenue for 2024 is projected at 2,219.98 billion yuan, with a net profit of 108.87 billion yuan, reflecting an 8.18% decline [6][7] - Among 33 sub-industries, 23 reported revenue growth, with chlor-alkali and textile chemicals showing significant profit increases of 262.84% and 125.27% respectively [7] - The sector's construction projects are slowing, with total ongoing projects at 380.64 billion yuan, a 10.83% increase year-on-year [9] Computer Industry - The computer industry saw a revenue increase of 15.90% in Q1 2025, with 56.14% of companies reporting positive growth [11][12] - The overall net profit for the industry in 2024 decreased by 41.73%, but the first quarter of 2025 showed a strong recovery [14] - The industry's average gross margin for 2024 was 25.51%, indicating a slight decline, while R&D expenses decreased slightly to 9.07% of revenue [15] Public Utilities - Lin Yang Energy's electric meter business achieved a revenue of 2.704 billion yuan in 2024, marking an 18.94% increase [18] - The company faced challenges with credit impairment losses totaling 144 million yuan, impacting overall profitability [18] - The overall net profit for Lin Yang Energy in 2024 was 753 million yuan, a decrease of 27.00% year-on-year [17]

Group 1: Key Insights - The mechanical equipment industry is experiencing profit pressure in 2024 due to insufficient downstream demand and investment intensity, but signs of weak recovery are observed in Q1 2025, with financial indicators improving [2][7][8] - The overall revenue for the mechanical equipment sector in 2024 was CNY 1,999.57 billion, a year-on-year increase of 4.99%, while net profit decreased by 8.07% to CNY 105.31 billion [8] - In Q1 2025, the mechanical equipment industry achieved revenue of CNY 454.01 billion, a year-on-year increase of 10.16%, and net profit of CNY 32.81 billion, up 24.44% year-on-year [8] Group 2: Subsector Performance - In 2024, the engineering machinery sector showed a bright performance with a revenue increase of 2.99% to CNY 357.23 billion, while other subsectors faced profit pressure [9] - For Q1 2025, the engineering machinery sector continued its growth trend with revenue of CNY 96.44 billion, a year-on-year increase of 10.62%, and net profit up 31.15% [9] Group 3: Electronic Sector Insights - The company reported a total revenue of CNY 3.693 billion in 2024, a decrease of 14.22% year-on-year, with net profit dropping by 67.72% to CNY 246 million [11][12] - In Q1 2025, the company’s revenue fell by 8.17% to CNY 861 million, and net profit decreased by 18.76% to CNY 80 million [14] Group 4: AI and Computing Demand - Major North American tech giants are significantly increasing their capital expenditures, with a combined CAPEX guidance exceeding USD 320 billion for 2025, reflecting a 43% increase from 2024 [4][16] - The demand for AI computing power is expected to rise, driven by the integration of AI technologies into various business models, leading to sustained high global computing demand [18]

Group 1 - China State Construction signed new contracts totaling 1.52 trillion yuan from January to April, representing a year-on-year increase of 2.8% [1] - Yongpu Medical's subsidiary obtained a medical device business license valid until May 7, 2030, allowing it to engage in medical device retail and wholesale [1] - Ningbo Maritime received a government subsidy of 4.42 million yuan, which will impact its net profit for the fiscal year 2025 [1] Group 2 - Mingpu Optoelectronics obtained a patent for a magnetic powder core and its preparation method, enhancing its capabilities in magnetic materials technology [1] - Digital Zhitong plans to establish a wholly-owned subsidiary in Beijing with a registered capital of 5 million yuan [1] - Zhongmin Energy's shareholder plans to reduce its stake by up to 0.28% of the company's total shares [1][6] Group 3 - Tunnel Holdings' controlling shareholder intends to increase its stake in the company by investing between 250 million to 500 million yuan [1] - China Telecom appointed Liu Guiqing as the new President and COO [1] - Datang Power completed the issuance of 3 billion yuan in medium-term notes, with proceeds aimed at repaying debt and supplementing working capital [1] Group 4 - *ST Weihai won a bid for a flood control project worth 182 million yuan, accounting for 7.35% of its audited revenue for 2024 [1] - Huijin Tong announced a cash dividend of 0.0868 yuan per share, totaling 29.44 million yuan [1] - Xinkai Energy's shareholders plan to reduce their holdings by a combined total of 4% of the company's shares [1][39] Group 5 - Xinhuan Group's subsidiary won a 1.02 billion yuan nuclear power project contract [1] - Southern Airlines reported a 12.14% year-on-year increase in passenger turnover for April [1] - Xinjiang Torch plans to acquire 100% equity of Yushan Litai for 125 million yuan [1]

或股东代理人所持表决权的二分之一以上通过。 | 证券代码：688198 证券简称：佰仁医疗 公告编号：2025-015 | | | | --- | --- | --- | | 北京佰仁医疗科技股份有限公司 | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | 重要内容提示： | | | | 本次会议是否有被否决议案：无 | | ? | | 会议召开和出席情况 | | 一、 | | （一） 股东大会召开的时间：2025 年 5 月 15 日 | | | | （二） 股东大会召开的地点：北京市昌平区科技园东区华昌路 2 | 号公司会议室 | | | （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 | | | | 其持有表决权数量的情况： | | | | 普通股股东人数 66 | | | | 普通股股东所持有表决权数量 102,329,195 | | | | 例（%） | | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 74.4780 | | ...

上海君澜律师事务所 关于北京佰仁医疗科技股份有限公司 致：北京佰仁医疗科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》《上市公司股东会规则》（以下简称"《股东会规则》"）等法 律、法规、规章、规范性文件及《北京佰仁医疗科技股份有限公司章程》（以下 简称"《公司章程》"）的规定，上海君澜律师事务所（以下简称"本所"）接 受北京佰仁医疗科技股份有限公司（以下简称"公司"）的委托，指派本所律师 出席公司2024年年度股东大会（以下简称"本次股东大会"），并就本次股东大 会的召集、召开程序及表决程序、表决结果等事项出具本法律意见书。 本法律意见书仅供本次股东大会之目的使用。本所律师同意将本法律意见书 随公司本次股东大会其他信息披露资料一并公告。 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责的精神，对本 次股东大会所涉及的有关事项和相关文件进行了必要的核查和验证，现出具法律 意见如下： 一、 本次股东大会的召集、召开程序 公司董事会于 2025 年 4 月 23 日召开第三届董事会第九次会议，审议通过 了《关于 <公司 ensp="ensp" 年度总经理工作 ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2025-015 北京佰仁医疗科技股份有限公司 2024年年度股东大会决议公告 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 66 | | --- | --- | | 普通股股东人数 | 66 | | 2、出席会议的股东所持有的表决权数量 | 102,329,195 | | 普通股股东所持有表决权数量 | 102,329,195 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 74.4780 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 74.4780 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 1、表决方式 会议采取现场及网络方式投票表决，表决程序符合《公司法》和《公司章程》的 规定。 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会 ...

上海君澜律师事务所 关于北京佰仁医疗科技股份有限公司 2024 年年度股东大会的法律意见书 致：北京佰仁医疗科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》《上市公司股东会规则》（以下简称"《股东会规则》"）等法 律、法规、规章、规范性文件及《北京佰仁医疗科技股份有限公司章程》（以下 简称"《公司章程》"）的规定，上海君澜律师事务所（以下简称"本所"）接 受北京佰仁医疗科技股份有限公司（以下简称"公司"）的委托，指派本所律师 出席公司2024年年度股东大会（以下简称"本次股东大会"），并就本次股东大 会的召集、召开程序及表决程序、表决结果等事项出具本法律意见书。 本法律意见书仅供本次股东大会之目的使用。本所律师同意将本法律意见书 随公司本次股东大会其他信息披露资料一并公告。 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责的精神，对本 次股东大会所涉及的有关事项和相关文件进行了必要的核查和验证，现出具法律 意见如下： 一、 本次股东大会的召集、召开程序 1.1 本次股东大会由公司董事会召集。 公司董事会于 2025 年 4 月 23 日召开第三届董事会 ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2025-016 因此，经导管瓣中瓣系统的问世，无疑将为越来越多选择植介入生物瓣的术后患 者解决后顾之忧。 2、该产品与公司限位可扩张外科瓣配套使用可获得更佳瓣中瓣治疗效果 北京佰仁医疗科技股份有限公司 关于自愿披露创新产品"经导管瓣中瓣系统"获批注册的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，经国家药品监督管理局审查，北京佰仁医疗科技股份有限公司（以下简称 "公司"）全球首个以瓣中瓣的产品理念设计开发，专用于已植入人工生物瓣膜发生 损毁危及生命且面临外科手术高风险患者的Renato®经导管瓣中瓣产品获批注册。与之 前所有植入或经导管介入的人工生物瓣不同，该产品是针对人工生物瓣的解剖结构设 计开发，其结构与特性可在人工生物瓣膜流入端的瓣座部位实现稳固锚定，参照所有 植介入人工生物瓣流入端瓣均为规则圆形，以及各类人工生物瓣的内径尺寸，申报注 册产品每2毫米径差设计一个规格，以更精准地实现瓣中瓣锚定。该产品的注册和产业 化标志着人工生物瓣再介入治疗时代的开 ...